BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/26/2021 5:58:37 AM | Browse: 548 | Download: 1217
 |
Received |
|
2020-10-21 11:50 |
|
Peer-Review Started |
|
2020-10-21 11:51 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-12-03 23:17 |
|
Revised |
|
2020-12-25 14:42 |
|
Second Decision |
|
2021-01-20 13:22 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-01-21 18:44 |
|
Articles in Press |
|
2021-01-21 18:44 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-02-03 01:39 |
|
Typeset the Manuscript |
|
2021-02-22 00:42 |
|
Publish the Manuscript Online |
|
2021-02-26 05:58 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of enticavir dosage
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Guo-Qing Yin, Jun Li, Bei Zhong, Yong-Fong Yang and Mao-Rong Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Guo-Qing Yin, MD, PhD, Chief Doctor, Chief Physician, Department of Infectious Disease, Nanjing Zhong-Da Hospital, Southeast University School of Medicine, No. 87 Dingjiaqiao, Nanjing 210009, Jiangsu Province, China. yingq62@sina.com |
| Key Words |
Chronic hepatitis B virus infection; Low-level viremia; Therapeutic options; Entecavir; Dose; Efficacy |
| Core Tip |
Persistent low-level viremia (LLV), in addition to causing the progression of liver disease or hepatocellular carcinoma, may shed light on the current plight of nucleos(t)ide analogs (NA) therapy. Since 2006, the authors focused on NA-refractory and participated in treating LLV patients. We presented the interferon-α switching therapy to treat LLV patient with failure of combined nucleoside plus nucleotide therapy. The current study scoured literature to shed light on the possibility of improving the antiviral effect of entecavir by increasing the dose. Here, we recommend that clinical trials involving entecavir should trial doses over more 1.0 mg/d for treating NA-refractory patients. |
| Publish Date |
2021-02-26 05:58 |
| Citation |
Yin GQ, Li J, Zhong B, Yang YF, Wang MR. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of enticavir dosage. World J Gastroenterol 2021; 9(8): 666-676 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i8/666.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i8.666 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
